Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men.

doi:10.1111/bcp.15245

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men.

British journal of clinical pharmacology - 1 Jul 2022

Türkmen Deniz, Masoli Jane A H, Kuo Chia-Ling, Bowden Jack, Melzer David, Pilling Luke C

Abstract excerpt

OBJECTIVE: To estimate the effect of rs4149056 (SLCO1B1*5) genotype (decreases statin transport) on cholesterol control and treatment duration in male and female primary care patients prescribed common statin medications. METHODS AND ANALYSIS: This study comprised 69 185 European-ancestry UK Biobank cohort participants prescribed simvastatin or atorvastatin (aged 40-79 years at first prescription, treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Transport and Resistance Mechanisms

Share to Genotype

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Lipoproteins and Cardiovascular Health

Share to Liver-Specific Organic Anion Transporter 1

Share to Simvastatin

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 35083771
DOI: 10.1111/bcp.15245
PMCID: PMC9305522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men.PMID 35083771Read ↗

Statin treatment effectiveness and the <i>SLCO1B1</i>*5 reduced function genotype: long-term outcomes in women and menSemantic proximity Read ↗

SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.Semantic proximity Read ↗

SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care.Semantic proximity Read ↗

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.Semantic proximity Read ↗

Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care dataSemantic proximity Read ↗

Predictive value of<i>SLCO1B1</i>c.521T>C polymorphism on observed changes in the treatment of 1136 statin-usersSemantic proximity Read ↗

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users.Semantic proximity Read ↗

Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.Semantic proximity Read ↗

SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort.Semantic proximity Read ↗

Point-Counterpoint: SLCO1B1 Genotyping for Statins.Semantic proximity Read ↗

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.Semantic proximity Read ↗

Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.